Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Home Administration of Microdose Psilocybin
NCT06450210Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin (5 arms), sponsored by Johns Hopkins University. Primary endpoints: Systolic and Diastolic Blood pressure, Heart rate and 2 more. Started Dec 2024; status: completed.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT06450210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450210.